Recent articles
Is CRISPR Therapeutics Stock a Buy?
The gene-editing pioneer is a favorite among biotech investors and its stock is hitting new highs.
2 Top Cancer Treatment Stocks To Watch In July
These hidden gems have the potential to deliver significant returns to their shareholders over the long run.
These 2 Pharma Stocks Could Be Top Stocks in 2020
These pharma stocks are undervalued, and could be solid picks over the long term.
Is Dynavax Technologies Stock a Buy?
This stock has the potential to break new highs with its key hepatitis B vaccine and emerging vaccine-adjuvant platform for COVID-19 vaccines.
2 Biotech Stocks That Could Soar in 2020
These companies offer promising pipelines that could deliver in the long term.
Better Buy: Illumina vs. Guardant Health
Which stock wins in a matchup between these two healthcare stocks?
2 Top Cancer Treatment Stocks to Buy in June
If you have cash to spare, these cancer stocks are set to soar.
3 Drug Stocks That Could Soar in 2020
Have extra cash to spare? These drug stocks are significantly undervalued and could make you wealthy in the long run.
Is Aurinia Pharmaceuticals Stock a Buy?
This biopharma’s drug could be a home run for investors.
Better Buy: CRISPR Therapeutics vs. Intellia
Which gene editing stock wins this matchup?
Is Acadia Pharmaceuticals a Buy?
A strong Q1 performance set the tone, but commitment to its strategy will be key to drive the stock higher.
Is Amarin Stock a Buy?
Record revenues, international growth, and a potential legal strategy may provide upside.
Is Exact Sciences Stock a Buy?
Q1 results were mixed, but the company’s strategy may be key for top-line growth ahead.
Is Catalyst Pharmaceuticals a Buy?
Several catalysts could drive this biopharma higher, but there are some significant risks ahead, too.
Your 2 Top Profit Opportunities in 2020
These two underrated biotech stocks have the potential to soar.
Is Exelixis a Buy?
Cheap and ready to outperform, this under-the-radar biotech stock could be a winner.
Is BioMarin Pharmaceutical Stock a Buy?
Is this a prime opportunity for investors to buy the gene therapy drugmaker?
This 1 Stock Is a Good Buy During the Coronavirus Sell-Off
Acadia Pharmaceuticals' track record of success and strong pipeline offers an attractive long-term opportunity for investors, especially at a depressed price.
Can Halozyme Therapeutics Continue Its Momentum in 2020?
The biopharma's strategic moves in 2019 may set the company up for long term growth.
Here's Why Clovis Oncology Has Upside Potential in 2020
The cancer-drug maker has a novel medicine that may provide growth opportunities in other areas of cancer.